Loading…
← CockpitCompetitor Analysis › REPL Replimune Group, Inc.Open in the cockpit ↗

Replimune Group, Inc.REPLCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops oncolytic virus therapies that infect and kill tumor cells while triggering an immune response against cancer.

Momentum leader 100
Mkt cap
$1.88B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$65.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.5%
Hurdle
n/a
no reverse DCF
Next earnings
76 days
2 Feb 2027
Close · USD$19.81
1D+0.6%
1W-9.0%
1M+73.5%
3M+41.0%
6M+321.5%
YTD+103.8%
1Y+120.4%
ATR %6.6%
Beta1.24
52w lowhigh15.8% off high

What Replimune does

Develops oncolytic virus therapies that infect and kill tumor cells while triggering an immune response against cancer.

Has no approved product, so it earns nothing from sales and pays for development by selling shares and other capital raises. Everything rests on RP1, an engineered herpes virus injected into tumours to kill cancer cells and prompt an immune response, studied alongside nivolumab in melanoma.

Products and services

  • RP1 (vusolimogene oderparepvec, melanoma)
  • Oncolytic virus pipeline in other solid tumors

Customers

  • Oncologists/dermatologic oncologists (post-approva

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Oncolytic virus immunotherapy

What could go right

  • RP1 potential approval and launch
  • Combination immunotherapy expansion

What could go wrong

  • Regulatory and clinical trial risk
  • Competitive immuno-oncology landscape

Moat: narrow (IP / patents, process know-how). Proprietary herpes-virus-based oncolytic platform engineered to boost anti-tumor immune response.

Headquarters: Woburn, Massachusetts, US · Founded: 2015 · Employees: 465

Named competitors

Replimune at a glance

Size Replimune (REPL) is a United States Health Care company (Biotechnology) with a market value of $1.88B, the 1808th largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.81 on 18 Nov 2026.

Performance Over six months the shares gained 321.5%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 19 in its peer set.

Short interest Short interest is 26.0% of the free float (30 Oct 2026).

Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).

Relative performance

20040021 May 202621 Aug 202618 Nov 2026REPL 384Peer median 93
Six months, rebased to 100: Replimune against the median of its 20 peers (local-currency closes).

Replimune financials

Reported figures in USD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$6.57M-$6.53M-$3.50M-$2.65M-$2.45M
EBITDA-$265M-$315M-$260M-$234M-$178M
Net income-$271M-$314M-$247M-$216M-$174M
Free cash flow-$246M-$285M-$199M-$191M-$130M
Capital expenditure$223,000$4.22M$6.69M$5.66M$2.27M
Total debt$127M$112M$76.2M$75.9M$60.8M

Quarterly statements and history in the cockpit →

Replimune competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%BCRXSEPNTRAX300601688520MRVITRVICOAGZBIORXRXSTOKALMRREPL6-month return →1-month return →
Up and to the right = strong over both horizons. Replimune is the large dot.

Replimune competitors and peer comparison

Head to head with its named competitors (REPL vs AMGN vs MRK vs CADL)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Replimune REPL$1.88B+321%n/an/an/an/a
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Merck & MRK$340B+23%+5%18%5.7×8.3%
Candel Therapeutics CADL$417M-31%n/an/an/an/a

How Replimune compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Replimune against its 20 peers (data as of 18 Nov 2026)
MeasureREPLPeer medianRank in peer set
1-month return+73.5%-6.2%highest of 20
6-month return+321.5%-4.7%highest of 19
Distance from 52-week high-15.8%-34.3%3rd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a

Questions

Who are Replimune's main competitors?
Named competitors: Amgen (Imlygic) (AMGN), Merck (MRK), Candel Therapeutics (CADL). The cockpit's measured peer set (industry) also includes BioCryst Pharmaceuticals (BCRX), Septerna (SEPN), First Tracks Biotherapeutics (TRAX), Shenzhen Kangtai Biological Products (300601.SZ), Sinocelltech (688520.SS), Vera Therapeutics (VERA).
How has Replimune stock performed?
Over six months to 18 Nov 2026 the shares returned +321.5% against -4.7% for the median peer; over one year +120.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.